GLP-1 in Canada 2026: Approvals, CAD Prices, Provincial Coverage, and Telehealth

Canada is in a strange moment for GLP-1 access. Every major drug in the class is now approved here, but most provincial plans only pay for diabetes. The 2023–2024 Ozempic shortage is over. Zepbound finally launched in 2025. And on April 28, 2026, Canada became the first G7 country to approve a generic semaglutide — which is already pulling list prices down. This guide pulls all of that into one place: what's approved, what it costs in Canadian dollars, what your province actually covers, and how to legitimately get a prescription through a Canadian telehealth service.

Direct answer: As of August 2026, Canadians have access to Ozempic (semaglutide, diabetes), Wegovy (semaglutide, obesity), Rybelsus (oral semaglutide, diabetes), Mounjaro (tirzepatide, diabetes), Zepbound (tirzepatide, obesity, approved May 13 2025, in pharmacies July 2025), and Saxenda (liraglutide, obesity). Self-pay pricing runs roughly $230–$280 CAD/month for Ozempic, $400–$570 CAD/month for Wegovy, $300–$540 CAD/month for Mounjaro and Zepbound, and $350–$450 CAD/month for Saxenda. Provincial plans (ODB in Ontario, RAMQ in Quebec, BC PharmaCare, Alberta Blue Cross, etc.) only cover GLP-1s for type 2 diabetes, almost never for weight loss. Private insurance covers obesity inconsistently and is bought plan by plan: Felix, the largest Canadian virtual weight-loss clinic, reports that fewer than 5% of its weight-management patients are fully covered by insurance. The Ozempic shortage that defined 2023–2024 is resolved as of January 2025. Buying from US pharmacies and importing into Canada is not legal under the Food and Drugs Act for personal use without proper authorization. The cheaper path is a Canadian telehealth provider (Felix, Maple, Pocketpills, Walk In) plus generic semaglutide, which stopped being theoretical in May 2026: generics reached Canadian pharmacy shelves the week of May 19, 2026 at roughly $100 CAD/month, and on June 29, 2026 Health Canada approved Sevmia, the first generic semaglutide licensed for weight management rather than diabetes.

What's Approved in Canada (August 2026)

Every date above is the Notice of Compliance date in Health Canada's NOC database; marketing dates come from the Drug Product Database.

A few things worth flagging:

• Canada lagged the US on Wegovy. Health Canada approved it in 2021 but Novo Nordisk only launched it commercially here in May 2024 because of global shortage allocation. That's also why the 2023–2024 Ozempic shortage was so severe in Canada — Novo was preserving semaglutide capacity for the more recently launched US Wegovy market.
• Zepbound was approved two years after the US (US approval was November 2023). Canadian Zepbound is sold only as the multi-dose KwikPen — no vial-and-syringe option.
• Rybelsus (the oral semaglutide pill) has been authorized in Canada since March 30, 2020 and on pharmacy shelves since that April — only months behind its September 2019 US approval. Three lower tablet strengths (1.5 mg, 4 mg and 9 mg) were authorized in October 2024 and reached the market in March 2026, which is the only thing about Rybelsus that is genuinely new.
• Generic semaglutide is no longer diabetes-only. The first two generics (Dr. Reddy's, Apotex) reference Ozempic and carry the diabetes indication, but Health Canada approved Sevmia — Apotex's generic of Wegovy, developed with Orbicular Pharmaceutical Technologies — for the once-weekly treatment of patients 12 years and over for chronic weight management on June 29, 2026. Health Canada said that day it was still reviewing six other generic semaglutide submissions; one of those, Aspen Pharmacare's, was approved on July 17, 2026.

List Prices in Canadian Dollars

Self-pay numbers from across major Canadian retail pharmacies, May 2026:

Add roughly $10–$15 in dispensing fees per fill and $5–$15 in delivery if you order online.

For context: as of August 2026 Novo's US NovoCare Pharmacy self-pay channel prices Wegovy at $349 USD/month for the 0.25–2.4 mg doses, and Lilly's LillyDirect self-pay prices for Zepbound start at $299 USD/month at 2.5 mg. Converted at any recent exchange rate, Canadian and US direct-to-patient cash prices are now broadly comparable — the older claim that Canada is dramatically cheaper no longer holds for the brands.

What Changed Since the Generic Launch (May–August 2026)

Canadian semaglutide pricing reset over six weeks in mid-2026. The sequence:

What that means if you are paying cash:

• Generic semaglutide runs about $100 CAD/month. That is the figure pharmacies quoted CBC in the first week of sales, against the $400/month one B.C. patient in the same report had been paying for brand Ozempic once her dose escalated. A Windsor-Essex pharmacist expects $75/month once more generics land.
• The Ozempic generics are diabetes-labelled; Sevmia is the weight-management one. Sevmia was still listed as "Approved" rather than "Marketed" in Health Canada's Drug Product Database in August 2026, and Apotex had not published a Canadian pharmacy price for it, so generic-priced semaglutide carrying an actual weight-management licence is approved but not yet on a shelf with a number on it.
• Brand Ozempic no longer costs more than generic if you use the savings card. Novo's own announcements say patients can find eligibility details and get a card at Ozempic.ca, that the card can be used at pharmacies across Canada excluding Quebec, and that the savings are applied automatically at Novo Nordisk Care Rx operated by Rexall and select online telehealth and retail partners.
• Demand moved the same day. Felix's chief pharmacy officer told CBC the platform saw 14 times the usual number of weight-loss visit requests in the first 24 hours after generics went on sale, a majority of them from new patients.
• More generic semaglutide submissions are under Health Canada review. The department said on June 29, 2026 that six were outstanding; Aspen Pharmacare's was approved on July 17, 2026, leaving the rest pending. That queue is the main reason to expect the $100 figure to keep drifting down rather than up.

Ozempic vs Wegovy Price in Ontario

Same molecule, two products, two very different Ontario price realities — and the gap widened on June 30, 2026 when generics hit the provincial formulary.

Read the last two columns together, because that is the whole story. Ozempic's ODB benefit price is $227.94 per pen, but now that interchangeable generics are listed the ministry reimburses only $78.14 — the generic price. Insist on brand Ozempic under ODB and you cover the spread yourself, unless Novo's savings card closes it.

Wegovy appears nowhere in the ODB formulary's semaglutide listings, at any strength. The reason is in the Limited Use criteria the whole semaglutide class is listed under: coverage is "for the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate" (LU code 667), with no concurrent GLP-1, DPP-4 inhibitor or oral semaglutide. Weight management is not in that sentence. Self-pay Wegovy in Ontario is the same $400–$570 CAD/month you would pay in any other province.

So the honest Ontario answer for someone treating obesity: Ozempic and its generics are cheap but only reachable through a type 2 diabetes diagnosis, and Wegovy is the on-label option that nothing public pays for. Sevmia is the first product that could break that pattern — weight-management semaglutide at generic pricing — but it needs a pharmacy price and an ODB listing first, and it had neither as of August 2026.

Public Coverage by Province

The pattern is consistent across the country: public plans pay for GLP-1s in diabetes, not in obesity. Below is what each major plan covers as of May 2026.

Ontario — ODB (Ontario Drug Benefit)

Covers Ozempic, its two generics and Rybelsus for type 2 diabetes, under Limited Use code 667: "when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate". A second oral agent is not part of that criterion. Mounjaro is not an ODB benefit — a formulary search for tirzepatide returns no products at all. Wegovy, Zepbound and Saxenda are not covered for weight management. Seniors over 65 and ODSP recipients are the largest beneficiaries.

Quebec — RAMQ

Public prescription drug insurance covers Ozempic and Rybelsus for diabetes; patients pay a monthly deductible plus coinsurance set annually by RAMQ, up to a monthly maximum. Wegovy and Saxenda for obesity are not on the formulary. Quebec also has unique structural coverage: residents must be enrolled in either RAMQ's public plan or a private plan — there is no opt-out.

British Columbia — PharmaCare

Covers Ozempic for type 2 diabetes when first-line agents (metformin) haven't achieved adequate glycemic control. Wegovy is not a PharmaCare benefit: the ministry's own Drug Information Sheet lists its PharmaCare status as "Under Review" and put it out for public input between March 26 and April 22, 2025 — and the indication under review is narrow, covering only adults with a BMI of 27 or higher and established cardiovascular disease, not weight management generally. The same sheet puts the annual cost of therapy at $5,471. Zepbound and Saxenda are self-pay or private-insurance.

Alberta — Alberta Blue Cross / Alberta Health

Covers GLP-1s for diabetes via Alberta Health under the Step Therapy framework — patients usually need documented failure of metformin first. Special authorization required. Weight-loss indications are not covered.

Atlantic Canada (NS, NB, PEI, NL)

Most limited. Nova Scotia covers GLP-1s under its diabetes assistance and Family Pharmacare programs with prior authorization for diabetes only. New Brunswick and Newfoundland generally require special authorization for diabetes coverage and offer essentially no obesity coverage. PEI similarly restricts to diabetes.

Federal plans (NIHB, PSHCP, Veterans Affairs)

The Non-Insured Health Benefits program for First Nations and Inuit covers Ozempic and Rybelsus for diabetes after step therapy. The Public Service Health Care Plan and Veterans Affairs follow similar rules — diabetes yes, obesity case-by-case with prior authorization.

The blunt summary: if you're using a GLP-1 for weight loss in Canada, you should plan on paying out of pocket or through private insurance.

Private Insurance Coverage

There is no reliable public figure for what share of Canadian employer plans cover GLP-1s for obesity, and numbers circulating online generally trace back to nothing checkable. What there is comes from providers' own patient data, and it is not encouraging: Felix reports that fewer than 5% of its weight-management patients are fully covered by insurance, and 86% of those without a savings plan pay entirely out of pocket, while its pricing page says about 40% of patients get some or all of their first fill covered. Read together: partial coverage is common, full coverage is rare.

What you'll see by insurer:

• Manulife — May cover Wegovy under select plans; Ozempic typically diabetes-only.
• Sun Life — Optional weight-management rider; usually requires BMI ≥30 (or ≥27 with comorbidity), prior authorization, and step therapy.
• Canada Life — Customizable; the company publishes a specific Prior Authorization form for Ozempic, Rybelsus, and other GLP-1s requiring A1c history and prior agent failure.
• Blue Cross (Pacific Blue Cross, Medavie, etc.) — Coverage varies by employer; weight-loss often an add-on rider.
• GreenShield Canada — May cover with strict criteria; prior authorization required.

Find your insurer's drug-specific prior authorization form before you ask a prescriber for anything, because the form is where the criteria are actually written down. Canada Life publishes three: a combined GLP-1 form covering Ozempic, Rybelsus, Wegovy and Mounjaro, plus standalone forms for Wegovy (semaglutide) and Zepbound (tirzepatide), all in the M6453 series, with a separate M7520 version for Public Service Health Care Plan members. Manulife publishes its own Group Benefits Drug Prior Authorization form for Wegovy. A drug having its own form means the insurer assesses it — it is not a promise that your specific plan bought the benefit.

Even with coverage, expect coinsurance and an annual or lifetime cap — your plan booklet, not a general figure, is what settles this. The pattern with new GLP-1 entrants is that insurers assess the diabetes indication first and treat the weight-management indication as a separate decision.

Shortage Status

Canada's GLP-1 supply situation has been formally stabilized since January 2025. The key dates, all from Health Canada's own supply notice:

• April 6, 2023 — Health Canada published its supply notice on GLP-1 receptor agonists, naming Ozempic (semaglutide), Trulicity (dulaglutide) and Mounjaro (tirzepatide) as affected by high global demand. Its advice to patients was to contact the pharmacy well before a current supply ran out.
• March 2023 — British Columbia restricted the dispensing of Ozempic to non-residents after large US-based volumes were filled at BC pharmacies.
• June 4, 2024 — Last content update to the supply notice before resolution.
• January 27, 2025 — Health Canada added a "Resolution of shortage" update to that notice: "The supply of Ozempic and other GLP-1 receptor agonists has stabilized and is available across the country."
• 2025–2026 — No active national shortage on that notice, though localized stock-outs of specific dose pens can still happen at individual pharmacies.

More generic semaglutide entering the market should further ease pressure on the supply chain.

Buying From the US — Don't

A small but persistent group of Canadians, often near the Quebec–Vermont or BC–Washington borders, ask whether they can fill cheaper US prescriptions and bring them home. Short answer: importing prescription drugs into Canada for personal use without proper authorization is not permitted under the Food and Drugs Act.

The specifics:

• Health Canada and CBSA enforce the rule jointly. They can seize, destroy, or order removal of any health product believed to contravene the Act, whether it comes by mail, courier, or in your luggage.
• There is a narrow personal-use exemption for a 90-day supply of a drug you were already taking before arrival, in original packaging, with documentation — but it does not cover routinely buying a cheaper US supply to bypass Canadian pricing.
• Online "Canadian pharmacy" sellers based offshore that ship internationally are a separate enforcement category and not the same as licensed Canadian retail pharmacies.

In the other direction, BC restricted Ozempic exports to non-Canadians in 2023 partly because so many US patients were having Canadian pharmacies fill their prescriptions during the US shortage.

The point: the legal path for a Canadian is a Canadian prescription filled at a Canadian pharmacy.

GLP-1 Patches in Canada: There Aren't Any

Search demand for "GLP-1 patches Canada" is real. The product is not. No transdermal GLP-1 patch is authorized by Health Canada, and none is authorized by the FDA or any other major national regulator either.

The obstacle is physical, not bureaucratic. Semaglutide is a 31-amino-acid peptide with a molecular weight around 4,114 daltons. Passive absorption through the stratum corneum, the skin's outer barrier, is generally limited to molecules under about 500 daltons — which is why the drugs that genuinely work as patches are small and fat-soluble: nicotine at 162 Da, estradiol at 272 Da, fentanyl at 336 Da. Semaglutide is roughly eight times over that ceiling, and skin proteases would cleave whatever fraction did cross.

Health Canada's January 21, 2026 advisory on unauthorized GLP-1 products describes the authorized ones as coming "in injectable formats or as oral tablets." There is no third format. Anything sold in a Canadian store or on a Canadian-facing website as a "GLP-1 patch," "semaglutide patch" or "GLP-1 support patch" is a supplement — the disclosed ingredients are typically berberine, cinnamon extract, B vitamins and L-glutamine — not a GLP-1 drug.

The one-step check is the same one Health Canada recommends for counterfeit injectables: a legitimate GLP-1 product sold in Canada carries an eight-digit Drug Identification Number on the label that you can look up in Health Canada's Drug Product Database. Patches do not have one, because there is nothing to license.

Telehealth Options Inside Canada

Several Canadian platforms offer end-to-end online assessment and prescription for GLP-1s. Contrary to a common belief, price is one of the few things a prescription drug can be advertised on in Canada — Felix, for one, publishes its program fees and medication price ranges openly. What platforms cannot do is advertise a prescription drug's benefits to the public, which is why the marketing talks about programs rather than results.

A few specifics worth highlighting:

• Felix's pricing reset. On May 12, 2026 Felix announced semaglutide savings of up to 65%, saying the change "may take effect as early as May 29, pending product availability" — so treat May 29 as the earliest date, not a guarantee. The same release cites an Angus Reid survey it commissioned in December 2025 in which 28% of Canadians living with overweight or obesity said they would consider a GLP-1 at a hypothetical $100 per month, against 5% at $400. Those are stated intentions in a hypothetical scenario, not observed behaviour.
• Insurance handling. Felix submits private insurance claims directly and says about 40% of patients get some or all of their first treatment fill covered — though fewer than 5% end up fully covered.
• Initial assessment is not insured. Almost all Canadian telehealth platforms charge a private fee for the GLP-1 program assessment, which is rarely reimbursed by either provincial or private plans.

Canada vs the US — How the Numbers Compare

Headline: the manufacturers' US direct-to-patient channels have cut list prices far enough that the old "buy it in Canada" arbitrage has mostly closed on the brands. Where Canada is now genuinely ahead is generics — the US has no FDA-approved generic semaglutide, while Canadian pharmacies are selling one for roughly $100 CAD a month. That is the lever that may finally pull Canadian obesity GLP-1 costs into the $100–$150 CAD/month range, once a weight-management generic actually reaches shelves.

What People Get Wrong About GLP-1 in Canada

• "Ozempic is covered by OHIP." Only for diabetes that has failed first-line therapy. Off-label weight loss is not.
• "I can order Wegovy cheaper from the US." Importing GLP-1s for personal use without authorization isn't permitted. CBSA does seize shipments.
• "There's still an Ozempic shortage." Health Canada marked the shortage resolved on January 27, 2025, saying supply "has stabilized and is available across the country."
• "Generic Wegovy is still years away." It isn't. The April 28 and May 1, 2026 generics were diabetes-only, but Health Canada approved Sevmia, a generic semaglutide for chronic weight management, on June 29, 2026. What is still missing is a marketed product with a published Canadian pharmacy price, not an approval.
• "My benefits cover Wegovy because they cover Ozempic." Most insurers treat the obesity indication separately and require a different prior authorization.
• "Felix sells GLP-1s like a US telehealth company." Felix prescribes and routes to a partner pharmacy. It does publish its program fees and medication price ranges, but what you actually pay depends on the dose you titrate to.
• "Zepbound has been in Canada the whole time." No — Zepbound was approved May 13, 2025 and hit pharmacies in July 2025, about 18 months after the US.
• "I can get reimbursed by my province if my doctor writes a letter." Off-label weight-loss prescriptions are essentially never reimbursed by public plans regardless of letters.

Frequently Asked Questions

Is Wegovy available in Canada? Yes. Health Canada approved Wegovy in 2021, but Novo Nordisk only launched it commercially in Canada in May 2024 due to global supply allocation.

How much does Wegovy cost in Canada without insurance? Roughly $400–$570 CAD per month at retail pharmacies, with bulk purchases of three pens dropping the per-pen price to around $399.

Does OHIP cover Ozempic? Yes, but only for type 2 diabetes, and only under Limited Use code 667: when adequate glycemic control is not achieved on the maximum tolerated dose of metformin, or where metformin is contraindicated or inappropriate. It cannot be funded alongside another GLP-1, a DPP-4 inhibitor or oral semaglutide. Public coverage does not extend to Ozempic or Wegovy for weight loss.

Is Zepbound approved in Canada? Yes. Health Canada approved Zepbound on May 13, 2025, and it became available at Canadian pharmacies on July 9, 2025. It is sold only as a multi-dose KwikPen.

Can I import GLP-1 medications from the US into Canada? Not for routine personal use without proper authorization. Health Canada and CBSA can seize shipments. A narrow exemption exists for a 90-day supply of a drug you were already taking, with documentation.

Is there still an Ozempic shortage in Canada? No. Health Canada added a resolution notice on January 27, 2025 stating that supply of Ozempic and other GLP-1 receptor agonists "has stabilized and is available across the country." Localized stock-outs of specific dose pens can still occur.

Does generic Ozempic exist in Canada? Yes. Dr. Reddy's Laboratories received Health Canada approval on April 28, 2026 for a generic semaglutide injection for type 2 diabetes, making Canada the first G7 country to approve a semaglutide generic. It is sold under the plain name Semaglutide Injection — there is no separate brand name for it. Apotex's Apo-Semaglutide Injection followed on May 1, 2026, and Aspen Pharmacare's was approved on July 17, 2026.

Will generic semaglutide be available for weight loss? One already is approved. Health Canada authorized Sevmia, Apotex's generic of Wegovy, on June 29, 2026 for chronic weight management. What has not happened yet is a launch: Sevmia was still flagged "Approved" rather than "Marketed" in the Drug Product Database in August 2026, with no published Canadian pharmacy price. The generics you can actually buy today all carry the diabetes indication.

Is Felix or Maple better for GLP-1 in Canada? Felix is bigger and specializes in weight-loss-focused care including dose escalation support. Maple is a general telehealth platform with a Weight Medication Assessment add-on. For complex diabetes, an endocrinology specialist (e.g. LMC) is usually a better fit.

Does private insurance in Canada cover Wegovy? Sometimes, and less often than people assume. Weight-management drug coverage is something each employer elects when it buys the plan, so there is no useful national percentage. Felix's own patient data is the closest published Canadian figure: fewer than 5% of its weight-management patients are fully covered by insurance, though about 40% get some or all of a first fill covered. Wegovy coverage, where it exists, usually requires prior authorization and BMI documentation.

Why is Wegovy more expensive in Canada than Zepbound? The visible difference is patient support: Eli Lilly runs the Myzepbound program, which takes $40.56 to $171.42 CAD off Zepbound per month depending on dose, and there is no comparable Wegovy program in Canada. Novo has not published a rationale for its Canadian Wegovy list price, so treat any explanation beyond that as inference.

How much is Ozempic in Canada? Brand Ozempic self-pay runs $230–$280 CAD/month for the 0.25–1 mg pen and $280–$330 for the 2 mg pen, plus $10–$15 in dispensing fees. Since May 2026 there are two cheaper routes: generic semaglutide at roughly $100 CAD/month, and Novo Nordisk's Ozempic Savings Card, which took effect May 29, 2026 for Canadians with no public or private coverage and expanded on July 6, 2026 to those with private drug coverage — everywhere except Quebec. Under the Ontario Drug Benefit the listed price for every Ozempic pen is $227.94, but the ministry reimburses only $78.14.

What is the price of Ozempic vs Wegovy in Ontario? Self-pay, Ozempic is $230–$280 CAD/month and Wegovy is $400–$570 CAD/month — roughly double, for the same molecule at higher doses. Through the Ontario Drug Benefit the gap is much wider: Ozempic is a Limited Use benefit whose listed drug benefit price is $227.94 per pen but which the ministry now reimburses at $78.14, the generic price, while Wegovy does not appear in the ODB formulary's semaglutide listings at any strength and is reimbursed at nothing.

How much does Zepbound cost in Canada? Zepbound runs roughly $300–$540 CAD/month at retail depending on dose and pharmacy, and lands at $279–$400 CAD/month after Eli Lilly's Myzepbound patient support program, which takes $40.56 off at 2.5 and 5 mg, $114.55 at 7.5 and 10 mg, and $171.42 at 12.5 and 15 mg. It is sold in Canada only as the multi-dose KwikPen. No provincial plan covers it for weight management, so unless your employer plan bought a weight-management benefit, the after-PSP number is what you pay.

Is there a generic Zepbound in Canada? No. Every Canadian generic approved so far is semaglutide — Dr. Reddy's, Apotex's Apo-Semaglutide and Aspen's for the Ozempic indication, and Sevmia for the Wegovy indication. Health Canada has approved no generic tirzepatide, the molecule in Zepbound and Mounjaro, and the further generic submissions it says are under review are semaglutide as well. The Myzepbound support program, not a generic, is the discount that exists today.

What is the name of generic Ozempic in Canada? There is no single brand name, because the molecule is just semaglutide and each company labels it its own way. Apotex sells Apo-Semaglutide Injection (DIN 02568020 for the 0.68 mg/mL pen, DIN 02568012 for the 1.34 mg/mL pen). Dr. Reddy's Laboratories sells its version under the plain name Semaglutide Injection (DIN 02567806 and 02567814). Both are on the Ontario Drug Benefit formulary at $78.14 per pen. A third, Aspen-Semaglutide, was approved on July 17, 2026 but had not reached the market as of August 2026. The weight-management generic is a separate product, Sevmia, also from Apotex. You may see the Dr. Reddy's product called "Obeda" on some sites — no product under that name appears in Health Canada's Drug Product Database or its Notice of Compliance database.

Where do I find the Canada Life Wegovy form? Canada Life publishes a drug-specific "Drug Prior Authorization Form — Wegovy (semaglutide)" in its M6453 series on canadalife.com, separate from the combined GLP-1 form that covers Ozempic, Rybelsus, Wegovy and Mounjaro. Public Service Health Care Plan members use the M7520 version of the same form. You complete the plan member and coverage sections; your physician or nurse practitioner completes the clinical sections, including confirming that Wegovy is being used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. Completed forms go back to Canada Life by mail, fax or email. There is a matching standalone Zepbound (tirzepatide) form. Direct links to all three are in Sources below.

Does Manulife cover Zepbound? There is no single Manulife answer, because weight-management drug coverage is something each employer elects when it buys the plan rather than something the insurer applies across the board. Manulife's own group-benefits guidance names tirzepatide (Zepbound) among the Health Canada-approved obesity treatments and encourages plan sponsors to add weight-loss medication coverage — which tells you it is a benefit to be purchased, not a default. Manulife has also required prior authorization on Ozempic since April 5, 2023 and publishes a Wegovy-specific Group Benefits Drug Prior Authorization form. Check your plan booklet for a weight-management drug provision, then confirm Zepbound's prior authorization status with the number on your benefits card before your prescriber writes anything.

Are GLP-1 patches sold in Canada? Products marketed as GLP-1 patches are sold here, but none of them contains a GLP-1 drug and none is authorized by Health Canada. Semaglutide's molecular weight of roughly 4,114 daltons is about eight times the ~500-dalton ceiling for passive absorption through intact skin. Health Canada's January 2026 advisory describes authorized GLP-1 products as coming in injectable formats or as oral tablets, and nothing else.

Last reviewed: August 21, 2026

Sources

• Can you get GLP-1 drugs in Canada? — Canadian Medical Association
• Canada becomes the first G7 country to approve a generic version of semaglutide — Health Canada
• Canada approves second generic semaglutide — Health Canada
• Health Canada approves 1st generic version of Ozempic — CBC News
• With Canada approving 1st generic semaglutide, how will costs compare? — Global News
• Supply of Ozempic and other GLP-1 receptor agonists: Notice — Health Canada
• Bringing health products into Canada for personal use (GUI-0116) — Health Canada
• Zepbound (tirzepatide) Product Monograph — Lilly Canada
• Zepbound Now Available in Canada: Price, Dosages — GLP1Prices.ca
• How Much Does Wegovy Cost in Canada? — Maple
• Weight Loss Drugs Covered by Group Insurance in Canada — PolicyAdvisor
• Felix Health to Lower Semaglutide Pricing by Up to 65% — GlobeNewswire
• Felix Weight Loss Program Pricing — Felix Health
• Zepbound Canada: Cost, Dosing — Walk In Virtual Doctors
• B.C. PharmaCare Drug Information Sheet for semaglutide (Wegovy) — Government of British Columbia
• Drug Prior Authorization Form: Ozempic, Rybelsus, and other GLP-1s — Canada Life
• Canada approves first generic semaglutide for weight loss — Health Canada
• 1st generic semaglutide injection for weight loss approved: Health Canada — CBC News
• Apotex first to receive Health Canada approval for SEVMIA, a generic semaglutide for chronic weight management — Apotex
• Generic Ozempic is now about $100 a month across the country — CBC News
• Generic semaglutide to hit Canadian pharmacies this week at lower cost — Global News
• Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic — Novo Nordisk Canada
• Ozempic Savings Card Program Expanded for Patients with Private Coverage — Novo Nordisk Canada
• Formulary search: semaglutide — Ontario Drug Benefit Formulary, Ontario Ministry of Health
• Limited Use note 667, semaglutide — Ontario Drug Benefit Formulary
• Thinking about buying GLP-1 drugs like Ozempic or Mounjaro? Beware of fake or unauthorized products — Health Canada
• GLP-1 Patch Scams: The Science Doesn't Support the Hype — Science-Based Medicine
• Drug Prior Authorization Form: Wegovy (semaglutide) — Canada Life
• Drug Prior Authorization Form: Zepbound (tirzepatide) — Canada Life
• Drug Prior Authorization Form: Wegovy (semaglutide), PSHCP — Canada Life
• Group Benefits Drug Prior Authorization: Wegovy (semaglutide) — Manulife
• Benefits of weight-loss medication coverage — Manulife
• Ozempic, diabetes, weight loss, and your benefits coverage — Manulife
• Notice of Compliance (NOC) database — Health Canada
• Drug Product Database — Health Canada
• Wegovy self-pay pricing — NovoCare Pharmacy
• Zepbound self-pay pricing — LillyDirect